Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286289 | 0.89 | DRD3 (0.52) | DRD2DRD3RAB9ASLC6A3CYP3A4 | |
| SCHEMBL4285624 | 0.83 | RAB9A (0.44) | DRD2DRD3RAB9ACYP19A1SLC6A3 | |
| SCHEMBL4290152 | 0.78 | CYP3A4 (0.48) | DRD2DRD3RAB9ACYP19A1SLC6A3 | |
| SCHEMBL13899050 | 0.77 | LARS1 (0.58) | DRD2DRD3RAB9ALARS1CYP3A4 | |
| SCHEMBL13899052 | 0.76 | LARS1 (0.56) | DRD2DRD3RAB9ALARS1HRH1 | |
| SCHEMBL4283007 | 0.75 | SCN5A (0.57) | DRD2DRD3RAB9ASLC6A3CYP3A4 | |
| SCHEMBL4281549 | 0.75 | LMNA (0.48) | DRD2DRD3RAB9ASLC6A3CYP3A4 | |
| SCHEMBL4283782 | 0.74 | HTR2A (0.47) | DRD2DRD3RAB9ASLC6A3CYP3A4 | |
| SCHEMBL4281380 | 0.74 | SCN5A (0.60) | DRD2DRD3RAB9ASLC6A3CYP3A4 | |
| SCHEMBL4283324 | 0.74 | LMNA (0.44) | DRD2DRD3RAB9ACYP19A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | DRD2 573/4885DRD3 440/4885RAB9A 2414/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | DRD2 573/4885DRD3 440/4885RAB9A 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.